According to investigator’s assessment, all of 21 (100%) patients had an objective response to BRL-201 and 18 (85.7%) patients had a complete response (CR) as best response (Fig. 1). Seventeen of 21 (80.9%) patients had an ongoing objective response at 3 months, 16 of 21(76.2%) patients had a CR and 1 of 21 (4.8%) patients had a partial response. One of the two patients with a high level (≥80% ) PD-L1 expression achieved CR and still remained CR at 26 months after infusion...The high efficacy of BRL-201 in r/r B-NHL was also observed, with a best of response (BOR) of 100% and an ORR of 80.9% at 3 months.